GSK1904529A

Catalog No. A10440

GSK1904529A分别用27和25 nmol/L的IC(50)s选择性抑制IGF-IR和IR。
Catalog Num A10440
M. Wt 852
Formula C44H47F2N9O5S
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 1089283-49-7
Synonyms GSK-1904529A
SMILES CCC1=CC(=C(C=C1N2CCC(CC2)N3CCN(CC3)S(=O)(=O)C)OC)NC4=NC=CC(=N4)C5=C(N=C6N5C=CC=C6)C7=CC(=C(C=C7)OC)C(=O)NC8=C(C=CC=C8F)F
GSK1904529A分别用27和25 nmol/L的IC(50)s选择性抑制IGF-IR和IR。
Targets
Target Value
Insulin ReceptorIC50: 25nM
IGF-1RIC50: 27nM
B-Raf(V600E)IC50: >2μM
SykIC50: 3.2μM
VEGFR2IC50: 3.2μM
IKK3IC50: 3.2μM
AuroraBIC50: 4μM
FynIC50: 6.3μM
RSK1IC50: 6.3μM
LCKIC50: 8μM
AuroraAIC50: >8μM
p38αIC50: 10μM
PKCεIC50: 10μM
PKCθIC50: >10μM
ActRIIBIC50: >10μM
Akt1IC50: >10μM
Akt2IC50: >10μM
ALK5IC50: >10μM
CaMKK2IC50: >10μM
CDK2/CyclinAIC50: >10μM
EGFRIC50: >10μM
ErbB2IC50: >10μM
JNK1IC50: >10μM
JNK2IC50: >10μM
JNK3IC50: >10μM
p70S6KIC50: >10μM
PAK1IC50: >10μM
PCTAIRE1IC50: >10μM
PDK-1IC50: >10μM
PI3KαIC50: >10μM
PI3KβIC50: >10μM
PI3KδIC50: >10μM
PI3KγIC50: >10μM
ROCK1IC50: >10μM
SIK2IC50: >10μM
Src1IC50: >10μM
YAK3IC50: >10μM
IKK1IC50: 13μM
IKK2IC50: 13μM
JAK3IC50: 13μM
JAK2IC50: >16μM
ZAP70IC50: >20μM
ASK1IC50: >25μM
ErbB4IC50: >25μM
GSK-3βIC50: >25μM
ITKIC50: >25μM
MAPKAPK2IC50: >25μM
In vitro DMSO 120 mg/mL (140.85 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 11.74 mL 58.69 mL 117.37 mL
0.5 mM 2.35 mL 11.74 mL 23.47 mL
1 mM 1.17 mL 5.87 mL 11.74 mL
5 mM 0.23 mL 1.17 mL 2.35 mL

*The above data is based on the productmolecular weight 852. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.